| 摘要 |
The inventor has determined that the nucleocapsid protein from a hepatitis virus can induce the prothrombinase, fgl2. The inventor has further develope d that LF-A1 also induces fgl-2. This allows for the development of therapeuti c methods and compositions for modulating immune coagulation. In particular, inhibitors of the N-protein or gene or LF-A1 protein gene, or LF-A1 binding site on the fgl-2 promoter may be useful in inhibiting immune coagulation caused by a virus such as a hepatitis virus.
|
